Alastair Garfield
Chief Scientific Officer at Rhythm Pharmaceuticals, Inc. (RYTM)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $913K
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Aug 17SEC | RYTMRhythm Pharmaceuticals, Inc. | Sell Plan | 2,0078,051 held (−20%) | $116.11 | $233K | -25.8% |
| Aug 17SEC | RYTMRhythm Pharmaceuticals, Inc. | Sell Plan | 1,5566,495 held (−19%) | $117.08 | $182K | -26.4% |
| Aug 17SEC | RYTMRhythm Pharmaceuticals, Inc. | Sell Plan | 3,4003,095 held (−52%) | $118.28 | $402K | -27.1% |
| Aug 17SEC | RYTMRhythm Pharmaceuticals, Inc. | Sell Plan | 8002,295 held (−26%) | $119.17 | $95K | -27.7% |
- Sell
Chief Scientific Officer Alastair Garfield sold $233K of RYTM at $116.11 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Scientific Officer Alastair Garfield sold $182K of RYTM at $117.08 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Scientific Officer Alastair Garfield sold $402K of RYTM at $118.28 — cuts the stake by 52%; pre-scheduled 10b5-1 plan sale.
- Sell
Chief Scientific Officer Alastair Garfield sold $95K of RYTM at $119.17 — cuts the stake by 26%; pre-scheduled 10b5-1 plan sale.